This article is more than 5 years old. Information may no longer be current.

Vexim receives FDA approval for marketing of new cement system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Vexim announced recently that the U.S. Food and Drug Administration has approved the company’s Masterflow Injection System, designed for mixing and injecting orthopedic cement, for marketing within the U.S.

The Masterflow system, which was in development for nearly 2 years, controls the injection of ultra-high-viscosity cement for the treatment of vertebral fractures where reducing and stabilizing the fracture is the priority, according to a company press release.

Vexim acquired a worldwide license in January 2013 for the system, which is protected by international patents granted in the United States, Europe and China.

The new system enables the company to target the U.S. back trauma market (vertebral augmentation market), which is estimated to total $500 million, or 60% of the global market.

The company plans to release the system in Europe during the first half of 2015, according to the release.

Reference: www.vexim.fr.